In a few months, the Harvard-founded healthtech business basys.ai plans to introduce its services in India. The startup tracks, forecasts, and offers interventions to enhance treatment outcomes for better metabolic health using its own AI technology.
A healthtech business called basys.ai, which got its start in Harvard, claims that its proprietary technology can assist doctors make better clinical decisions while managing the metabolic health of their patients.
To deploy its platform in these areas, the business has started talks with healthcare providers in Singapore and India.
It is relying on the Ayushman Bharat Digital Mission of the Indian government, which intends to connect hospitals’ digital health solutions throughout the nation.
This programme is anticipated to make it possible for doctors in any hospital in India to consentorily share patient records with them. “We are interested in visiting India because we believe that this (the framework for a universal electronic health record) will become a reality within the next five years. In India in 2019, 77 million persons had type-2 diabetes.
Given that metabolic syndrome, a group of illnesses that raises the risk of developing cardiovascular disease or type-2 diabetes, affects one in three persons in the nation, there is a high burden of these diseases in India.
According to Amber, depending on the support it receives from potential investors, basys.ai may deploy the platform in India over the next few months.
Basys.ai intends to collaborate with hospitals as the construction of India’s unified health record system progresses in order to expand its AI (artificial intelligence) capabilities.
The startup only operates in the US at the moment. When she was enrolled in Harvard’s health data science programme, Amber met Jie Sun, his co-founder.
In 2020, the co-founders launched their business. Basys.ai has triumphed in a number of contests.
According to the agreement, basys.ai would collaborate with the diabetic centre to track and monitor other metabolic health conditions like kidney and cardiovascular illnesses and develop interventions for them. The full range of diabetes-related issues are now being addressed in collaboration with the research centre.
Patients and doctors are the two different user kinds for the startup’s platform. The startup now focuses mostly on physicians.
According to Amber, the platform uses a dashboard to give doctors access to patient data, including their history and present health state and suggested future measures. According to Amber, doctors typically have between 15 and 20 minutes to review a patient’s medical information, identify their health issues, and provide possible treatments.
They might end up reading the information quickly, which is bad for the patients,” warns Amber.
The co-founder continues, “The difference is that basys.ai employs AI to give the patient’s health summary and a list of useful points that the doctors can use. For now, patients can choose whether or not to use the platform. They can sync their glucose metre once they have registered on the platform. The platform would instantly load up with all the data that has ever been gathered.
Additionally, users have the option to connect their smartwatches with the site. In addition to glucose levels, the platform also gathers data on a person’s metabolic health, including blood pressure, heart rate, daily activity levels, calories burned, resting heart rates, and heart rate variability, if they are utilising equipment to track these metrics.
The platform analyses this data to determine whether or not the diabetes state is getting better. The option to manually enter the information is available to those who do not use a gadget to record their glucose levels.
“Up to this point, we’ve been attempting to make it provider-first so that the doctors can refer patients to the platform. The startup is also attempting to determine whether it is feasible to establish a B2C (business to consumer) platform.
Amber claims that basys.ai would aid hospitals in boosting profits and cutting costs. “Doctors would be able to treat more patients in a given amount of time under the fee-for-service model (where doctors and other healthcare providers get paid for each service delivered).
The firm is focusing on mental health in addition to building a B2C platform for patients in the US.
“Mental health is our next step. Although it’s a completely different game, it is a component of metabolic wellness, adds Amber. A few hospitals in the US are also being approached by the startup for similar collaborations.
Along with the money they have received from grants and competitions, Amber and Jie have also contributed their own funds to the development of their firm.
Basys.ai is currently in discussions with a few investors to raise their initial funding. The healthtech business is presently concentrating on growing its customer base and product offerings to obtain global “clinical approval.”